1014 related articles for article (PubMed ID: 19481011)
1. Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease.
Allen KL; Waldvogel HJ; Glass M; Faull RL
J Chem Neuroanat; 2009 Jul; 37(4):266-81. PubMed ID: 19481011
[TBL] [Abstract][Full Text] [Related]
2. Comparative cellular distribution of GABAA and GABAB receptors in the human basal ganglia: immunohistochemical colocalization of the alpha 1 subunit of the GABAA receptor, and the GABABR1 and GABABR2 receptor subunits.
Waldvogel HJ; Billinton A; White JH; Emson PC; Faull RL
J Comp Neurol; 2004 Mar; 470(4):339-56. PubMed ID: 14961561
[TBL] [Abstract][Full Text] [Related]
3. Effects of exogenous and endogenous cannabinoids on GABAergic neurotransmission between the caudate-putamen and the globus pallidus in the mouse.
Engler B; Freiman I; Urbanski M; Szabo B
J Pharmacol Exp Ther; 2006 Feb; 316(2):608-17. PubMed ID: 16214880
[TBL] [Abstract][Full Text] [Related]
4. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
[TBL] [Abstract][Full Text] [Related]
5. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.
Glass M; Dragunow M; Faull RL
Neuroscience; 2000; 97(3):505-19. PubMed ID: 10828533
[TBL] [Abstract][Full Text] [Related]
6. Synaptic and extrasynaptic GABA-A and GABA-B receptors in the globus pallidus: an electron microscopic immunogold analysis in monkeys.
Charara A; Pare JF; Levey AI; Smith Y
Neuroscience; 2005; 131(4):917-33. PubMed ID: 15749345
[TBL] [Abstract][Full Text] [Related]
7. An electron microscope immunocytochemical study of GABA(B) R2 receptors in the monkey basal ganglia: a comparative analysis with GABA(B) R1 receptor distribution.
Charara A; Galvan A; Kuwajima M; Hall RA; Smith Y
J Comp Neurol; 2004 Aug; 476(1):65-79. PubMed ID: 15236467
[TBL] [Abstract][Full Text] [Related]
8. The diversity of GABA(A) receptor subunit distribution in the normal and Huntington's disease human brain.
Waldvogel HJ; Faull RL
Adv Pharmacol; 2015; 73():223-64. PubMed ID: 25637443
[TBL] [Abstract][Full Text] [Related]
9. GABAergic neurotransmission in globus pallidus and its involvement in neurologic disorders.
Chen L; Yung WH
Sheng Li Xue Bao; 2004 Aug; 56(4):427-35. PubMed ID: 15322674
[TBL] [Abstract][Full Text] [Related]
10. GABAB and CB1 cannabinoid receptor expression identifies two types of septal cholinergic neurons.
Nyíri G; Szabadits E; Cserép C; Mackie K; Shigemoto R; Freund TF
Eur J Neurosci; 2005 Jun; 21(11):3034-42. PubMed ID: 15978014
[TBL] [Abstract][Full Text] [Related]
11. Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP.
Betarbet R; Greenamyre JT
Exp Neurol; 2004 Oct; 189(2):393-403. PubMed ID: 15380489
[TBL] [Abstract][Full Text] [Related]
12. Decreased GABAA and GABAB receptor functional activity in cannabinoid CB1 receptor knockout mice.
Urigüen L; García-Gutiérrez MS; Manzanares J
J Psychopharmacol; 2011 Jan; 25(1):105-10. PubMed ID: 20142297
[TBL] [Abstract][Full Text] [Related]
13. Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease.
Ochi M; Shiozaki S; Kase H
Neuroscience; 2004; 127(1):223-31. PubMed ID: 15219684
[TBL] [Abstract][Full Text] [Related]
14. Striatal Direct and Indirect Pathway Output Structures Are Differentially Altered in Mouse Models of Huntington's Disease.
Barry J; Akopian G; Cepeda C; Levine MS
J Neurosci; 2018 May; 38(20):4678-4694. PubMed ID: 29691329
[TBL] [Abstract][Full Text] [Related]
15. Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus.
Richfield EK; Herkenham M
Ann Neurol; 1994 Oct; 36(4):577-84. PubMed ID: 7944290
[TBL] [Abstract][Full Text] [Related]
16. GABAergic control of substantia nigra dopaminergic neurons.
Tepper JM; Lee CR
Prog Brain Res; 2007; 160():189-208. PubMed ID: 17499115
[TBL] [Abstract][Full Text] [Related]
17. Preproenkephalin messenger RNA-containing neurons in striatum of patients with symptomatic and presymptomatic Huntington's disease: an in situ hybridization study.
Albin RL; Qin Y; Young AB; Penney JB; Chesselet MF
Ann Neurol; 1991 Oct; 30(4):542-9. PubMed ID: 1838677
[TBL] [Abstract][Full Text] [Related]
18. Immunocytochemical studies of substance P and leucine-enkephalin in Huntington's disease.
Marshall PE; Landis DM; Zalneraitis EL
Brain Res; 1983 Dec; 289(1-2):11-26. PubMed ID: 6198034
[TBL] [Abstract][Full Text] [Related]
19. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
20. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease.
Albin RL; Reiner A; Anderson KD; Dure LS; Handelin B; Balfour R; Whetsell WO; Penney JB; Young AB
Ann Neurol; 1992 Apr; 31(4):425-30. PubMed ID: 1375014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
